Development of PLGA-based injectable delivery systems for hydrophobic fenretinide

Pharmaceutical Research

Volumn 27, Issue 10, 2010, Pages 2063-2074

  Wischke, Christian ^a,b   Zhang, Ying ^a   Mittal, Sachin ^c   Schwendeman, Steven P ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b INSTITUTE OF MATERIALS RESEARCH   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

controlled release; fenretinide; hydrophobic drug; in situ implant; s o w PLGA microparticle

Indexed keywords

1 METHYL 2 PYRROLIDINONE; DICHLOROMETHANE; FENRETINIDE; METHANOL; POLYGLACTIN; POLYSORBATE 80;

ARTICLE; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIGITAL IMAGING; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; IN VITRO STUDY; MICROENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; POROSITY; PREFORMULATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ABSORBABLE IMPLANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; FENRETINIDE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INJECTIONS; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; SOLVENTS; SURFACE PROPERTIES;

EID: 77957331565     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0202-y     Document Type: Article

References (36)

1. LR Beck DR Cowsar DH Lewis JW Gibson CE Flowers 1979 New Long-Acting Injectable Microcapsule Contraceptive System Am J Obstet Gynecol 135 419 26 114054 1:CAS:528:DyaL3cXhtFWmug%3D%3D
2. Tice T, Lewis D. Microencapsulation process. United States Patent US 4,389,330 (1983).
3. SP Schwendeman 2002 Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems Crit Rev Ther Drug 19 73 98 10.1615/CritRevTherDrugCarrierSyst.v19.i1.20 1:CAS:528:DC%2BD38XksFaltL0%3D (Pubitemid 34521249)
4. WL Jiang RK Gupta MC Deshpande SP Schwendeman 2005 Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens Adv Drug Deliver Rev 57 391 410 10.1016/j.addr.2004.09.003 1:CAS:528:DC%2BD2cXhtVSntbrO (Pubitemid 39550967)
5. C Wischke SP Schwendeman 2008 Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles Int J Pharm 364 298 327 10.1016/j.ijpharm.2008. 04.042 18621492 1:CAS:528:DC%2BD1cXhtlOnurjF
6. GL Amidon H Lennernas VP Shah JR Crison 1995 A Theoretical Basis for a Biopharmaceutic Drug Classification-the Correlation of in-Vitro Drug Product Dissolution and in-Vivo Bioavailability Pharm Res 12 413 20 10.1023/A: 1016212804288 7617530 1:CAS:528:DyaK2MXksVGqur8%3D
7. H Seong TK An G Khang SU Choi CO Lee HB Lee 2003 BCNU-loadedpoly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro Int J Pharm 251 1 12 10.1016/S0378-5173(02)00543-4 12527170 1:CAS:528:DC%2BD3sXis1Whsg%3D%3D (Pubitemid 36071455)
8. M Xie L Zhou T Hu M Yao 2007 Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts Anticancer Drugs 18 459 66 10.1097/CAD.0b013e328012bccd 17351398 1:CAS:528:DC%2BD2sXis1anurY%3D (Pubitemid 46712409)
9. RC Moon HJ Thompson PJ Becci CJ Grubbs RJ Gander DL Newton JM Smith SL Phillips WR Henderson LT Mullen CC Brown MB Sporn 1979 N-(4-Hydroxyphenyl) Retinamide-New Retinoid for Prevention of Breast-Cancer in the Rat Cancer Res 39 1339 46 421218 1:CAS:528:DyaE1MXktlaku7c%3D
10. N Hail HJ Kim R Lotan 2006 Mechanisms of fenretinide-induced apoptosis Apoptosis 11 1677 94 10.1007/s10495-006-9289-3 16850162 1:CAS:528: DC%2BD28XptF2rurg%3D (Pubitemid 44376243)
11. TA Hultin CM May RC Moon 1986 N-(4-Hydroxyphenyl)-All-Trans-Retinamide Pharmacokinetics in Female Rats and Mice Drug Metab Dispos 14 714 7 2877832 1:CAS:528:DyaL2sXislensA%3D%3D
12. U.S. National Institutes of Health. www.clinicaltrials.gov.
13. G Wolf 2003 Lipofuscin and macular degeneration Nutr Rev 61 342 6 10.1301/nr.2003.oct.342-346 14604266 (Pubitemid 37243712)
14. RA Radu Y Han TV Bui S Nusinowitz D Bok J Lichter K Widder GH Travis NL Mata 2005 Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases Invest Ophthalmol Vis Sci 46 4393 401 10.1167/iovs.05-0820 16303925 (Pubitemid 44264531)
15. A Garaventa R Luksch MS Lo Piccolo E Cavadini PG Montaldo MR Pizzitola L Boni M Ponzoni A Decensi B De Bernardi FF Bellani F Formelli 2003 Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma Clin Cancer Res 9 2032 9 12796365 1:CAS:528:DC%2BD3sXksVWqtbk%3D
16. BJ Maurer O Kalous DW Yesair XQ Wu J Janeba V Maldonado V Khankaldyyan T Frgala BC Sun RT Mckee SW Burgess WA Shaw CP Reynolds 2007 Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex Clin Cancer Res 13 3079 86 10.1158/1078-0432.CCR-06-1889 17505011 1:CAS:528:DC%2BD2sXlt1Krtb0%3D (Pubitemid 46849585)
17. I Orienti G Zuccari V Bergamante R Carosio R Gotti M Cilli PG Montaldo 2007 Fenretinide-polyvinylalcohol conjugates: New systems allowing fenretinide intravenous administration Biomacromolecules 8 3258 62 10.1021/bm7005592 17883277 1:CAS:528:DC%2BD2sXhtVKgtbvO (Pubitemid 350011650)
18. C Zou M Brewer X Cao R Zang J Lin Y Deng C Li 2007 Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts Gynecol Oncol 107 441 9 10.1016/j.ygyno.2007.07.077 17854871 1:CAS:528:DC%2BD2sXhtlyrt73F (Pubitemid 350167464)
19. T Okuda S Kawakami Y Higuchi T Satoh Y Oka M Yokoyama F Yamashita M Hashida 2009 Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles Int J Pharm 373 100 6 10.1016/j.ijpharm.2009.01.019 19429294 1:CAS:528:DC%2BD1MXltlSjsLo%3D
20. Dunn RL, English JP, Cowsar DR, Vanderbilt DP. Biodegradable in situ forming implants and methods of producing the same. United States Patent US 4.938,763 (1990).
21. MA Royals SM Fujita GL Yewey J Rodriguez PC Schultheiss RL Dunn 1999 Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys J Biomed Mater Res 45 231 9 10.1002/(SICI)1097-4636(19990605)45: 3<231::AID-JBM11>3.0.CO;2-H 10397981 1:CAS:528:DyaK1MXisVeqtbY%3D (Pubitemid 29165939)
22. HSPiP. Hansen solubility parameters in practice. http://www.hansen- solubility.com
23. SR Mao Y Shi L Li J Xu A Schaper T Kissel 2008 Effects of process and formulation parameters on characteristics and internal morphology of poly(D, L-lactide-co-glycolide) microspheres formed by the solvent evaporation method Eur J Pharm Biopharm 68 214 23 10.1016/j.ejpb.2007.06.008 17651954 1:CAS:528:DC%2BD1cXlsF2msw%3D%3D
24. F Formelli R Carsana A Costa F Buranelli T Campa G Dossena A Magni M Pizzichetta 1989 Plasma Retinol Level Reduction by the Synthetic Retinoid Fenretinide-a One-Year Follow-up-Study of Breast-Cancer Patients Cancer Res 49 6149 52 2529028 1:STN:280:DyaK3c%2Fgt12quw%3D%3D
25. T Camerini L Mariani G De Palo E Marubini MG Di Mauro A Decensi A Costa U Veronesi 2001 Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer J Clin Oncol 19 1664 70 11250995 1:CAS:528:DC%2BD3MXisFygs78%3D
26. DT Birnbaum JD Kosmala DB Henthorn L Brannon-Peppas 2000 Controlled release of beta-estradiol from PLAGA microparticles: The effect of organic phase solvent on encapsulation and release J Control Release 65 375 87 10.1016/S0168-3659(99)00219-9 10699296 1:CAS:528:DC%2BD3cXhtl2qsbw%3D (Pubitemid 30122940)
27. W-I Li K Anderson R Mehta P DeLuca 1995 Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method J Control Release 37 199 10.1016/0168-3659(95)00076-3 1:CAS:528:DyaK2MXhtVSgt7vO
28. R Bodmeier JW Mcginity 1988 Solvent Selection in the Preparation of Poly(Dl-Lactide) Microspheres Prepared by the Solvent Evaporation Method Int J Pharm 43 179 86 10.1016/0378-5173(88)90073-7 1:CAS:528:DyaL1cXhvFaksL8%3D
29. G Spenlehauer M Veillard JP Benoit 1986 Formation and characterization of cisplatin loaded poly(d, l-lactide) microspheres for chemoembolization J Pharm Sci 75 750 5 10.1002/jps.2600750805 3772745 1:CAS:528:DyaL2sXnt1yiug%3D%3D
30. FG Hutchinson 1986 Continuous release pharmaceutical compositions European Patent EP 58 481
31. Y Ogawa M Yamamoto S Takada H Okada T Shimamoto 1988 Controlled-Release of Leuprolide Acetate from Polylactic Acid or Copoly(Lactic Glycolic) Acid Microcapsules-Influence of Molecular-Weight and Copolymer Ratio of Polymer Chem Pharm Bull 36 1502 7 3138032 1:CAS:528:DyaL1cXks1Wgt7o%3D
32. BS Zolnik DJ Burgess 2008 Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres J Control Release 127 137 45 10.1016/j.jconrel.2008.01.004 18282629 1:CAS:528:DC%2BD1cXkt1OrtL4%3D
33. M Turk R Lietzow 2004 Stabilized nanoparticles of phytosterol by rapid expansion from supercritical solution into aqueous solution AAPS PharmSciTech 5 e56 10.1208/pt050456 15760053
34. CB Packhaeuser J Schnieders CG Oster T Kissel 2004 In situ forming parenteral drug delivery systems: an overview Eur J Pharm Biopharm 58 445 55 10.1016/j.ejpb.2004.03.003 15296966 1:CAS:528:DC%2BD2cXmsVGnsL0%3D (Pubitemid 39037247)
35. PD Graham KJ Brodbeck AJ McHugh 1999 Phase inversion dynamics of PLGA solutions related to drug delivery J Controlled Release 58 233 45 10.1016/S0168-3659(98)00158-8 1:CAS:528:DyaK1MXhsVentL8%3D (Pubitemid 29112894)
36. AG Ding SP Schwendeman 2004 Determination of water-soluble acid distribution in poly(lactide-co-glycolide) J Pharm Sci 93 322 31 10.1002/jps.10524 14705190 1:CAS:528:DC%2BD2cXhsFagu7g%3D (Pubitemid 38174255)